

Advertisement
Turner & Lawson



The best walking shoes for women to wear all day

Read Today's Paper

Tributes

10:56am Wednesday, September 2nd, 2026

Adelaide Today  11°/17° >

The Advertiser
We're for you

 Hi, George  



My
News


Today's
Paper

SA

World

Sport

Business

Opinion

Education

Lifestyle

Entertainment

Puzzles



Business [Stockhead](#)

Biocurious: It's spring, when a young



"Ooh that's nice but I would rather a statistically significant, randomised, double blinded trial readout." Pic: Getty Images


- Correlation is not causation** trial results are pending from Recce, Paradigm and Actinogen Medical
- The results are likely to make or break the companies' fortunes
 - Alzheimer's drug developer Actinogen mulls a potential 'plan B' depression trial

Spring has sprung and what's not to love? Swooping magpies, hayfever and torrential rain notwithstanding, of course.



Stockhead
As recent failed late-stage results have shown, failure amounts to a shattering Everything you need to know before the ASX opens

Good morning! Here's everything you need to know before the ASX flings open its doors and The sector needs a win or two ... but no pressure at all.



Stockhead
The review recommended the trial continue without modification, as did ASX rises in volatile July with healthcare best performer

The S&P/ASX 200 rose 1.54% in August as healthcare popped 19% to be top the performing sector for the month. The company confirmed a September timeline for the interim readout.

biometrics and independent review processes.”
My News Feed [Read More >](#)



Leaders & Companies



SA Business



Business

“It will be before the first siren of the Carlton v Fremantle 2026 grand final.”

Blood spilt as chair directors ousted at iconic Aussie company
You read that one here first!

Mayfair Hotel to be transformed after \$75m sale

Digital air traffic control towers not fit

The study enrolled 538 patients, who were randomised to receive either Zilosul or a placebo on a one-to-one basis, over a six-week treatment period.

The recruitment exceeded the targeted 466 patients. The study is being carried out across 57 sites, 41 of them in the US and 12 in Australia.

The primary endpoint is the change in pain intensity at day 112, as per weekly average measurements.



EXCLUSIVE Sydney



Victoria



SA Business

Major update in relation to Swans players' alleged sexual assault incident

Love affair twist in deadly fight between neighbours in Croydon

SA's billion-dollar businesses: Top 35 private companies named

Recce versus superbug

Synthetic antibiotic developer Recce tentatively hopes for interim results from its pivotal Indonesian phase III trial by the end of October.

RECOMMENDED TO FOLLOW

- Police Courts Sa
- AFL
- South Australia
- News
- Sport
- Weather

The study road tests the company's Recce 327 gel (R327G), for diabetic foot infections (DFIs).

How scammers now impersonate your bank

The need is apparent, given Indonesia's high diabetes rate.



Around 20 million adult Indonesians have the condition – often undiagnosed and one in three will develop diabetic leg ulcers

Trending now

Almost half of the hospitalised patients will require amputations.

Police & Courts

The interim analysis applying to the first 155 patients, recruited across five sites



Read More

Celebrity Life

Shock as vandals target


Dolly Parton's Hollywood star, steal flowers



Should the results stack up, Recce hopes the drug will be approved and commercialised in Indonesia next year.

Tragic detail after bank

Aussie trial, yet




Royals

Meghan faces hiring crisis over 'rude' interview claims



In May this year Recce signed a non-binding term sheet with a "le Middle Eastern pharma company" for a ten-year, exclusive multi-country

Horrific crash leaves mum haunted by 'horrendous screams'



Meanwhile, Recce is carrying out an Australian-based phase III DFI trial. The study aims for Australian and US approval.

SA Business

last month an ethics committee approved a trial protocol amendment, which enabled the addition of a new active-controlled, non-inferior Adelaide beauty empire arm.



Man sues Bunnings in shock \$6m fight



The 208 patients receive either R327G, or one of four physician-selected antibiotics for comparison reasons for mounting at Mount Remarkable



Royals

“Patient dosing continues under the existing trial protocol, with recruitment and treatment ongoing ahead of implementation of this newly approved Stockhead,” Recce says.

Former prince Andrew accused of ‘sex crimes’ in the US



Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.

CEO James Graham says the ethics approval means recruitment can be widened to moderate, below-the-knee cases with multiple ulcers.

Follow

Bank's sad call: 1921K wiped from Aussies



This accounts for around about 80% of the market.

Previously, the trial could only enrol below-the-ankle, mild cases with single ulcers. This cohort accounts for around 30% of the market.

“The is based on FDA accepted guidance and dramatically increases recruitment, market opportunity etcetera,” Graham says.

The company plans an interim analysis at the 104-patient mark. This is likely to occur in late 2027 or early 2028.

“R327G has the potential to become the first standard of care used by physicians for the treatment of DFIs,” Graham says.

R327 is one of four synthetic antibiotics Recce is developing.

The aim, of course, is to address the global problem of antibiotic-resistant superbugs.

Actinogen eyes Alzheimer’s breakthrough

In its pursuit of a better treatment for Alzheimer’s disease, Actinogen is comforted by late January’s ‘futility’ interim analysis which showed that continuing the pivotal trial would be – well – far from pointless.

Dubbed Xanamia, the pivotal phase IIb/III trial road tests Xanamem (emestedastat).

Xanamem targets the suspected role of excess brain cortisol levels in triggering the disease. The notion of cortisol’s involvement in the disease has been around for decades, but no one has quite been able to prove it.

Xanamem targets 11beta-hydroxy-steroid dehydrogenase type 1 (11beta-HSD1).

That's not a Holden Special Vehicle, but a cortisol-producing enzyme expressed in parts of the brain governing memory and mood.

In its full year results last Thursday, Actinogen confirmed the study remained on track for topline final results in November.

The company reports that 89% of participants (108) have moved on to an open-label extension study.

"The good news is that as people are on the drug for longer and we are not seeing any surprising safety concerns," says Actinogen CEO Dr Steven Gourlay.

Should the study pass master, Actinogen has agreed with the FDA and the European regulator on a streamlined further placebo-controlled pivotal trial of Xanamem.

"I'm feeling quite good about our program," Gourlay says.

"Our endpoints are clear and it is good high-quality drug development."

He stresses the trial relies on clinical outcomes – read: patient improvement – rather than high falutin' biomarker measures (our words).

Plan B from biotech space

In July the peer-reviewed British Journal of Psychiatry published a write-up of Actinogen's separate phase II proof-of-concept study.

The trial measured the effect of Xanamem on patients with major depression and cognitive impairment.

In short, the journal opined the drug was "worthy of further investigation."

Gourlay says an Alzheimer's therapy is "far and away" more valuable than a depression treatment.

But the company is open to pursuing a trial of depression in Alzheimer's patients.

"We are not saying we will or won't do it," he says.

"Maybe we can do a trial in older patients, perhaps with dementia or maybe not.

"If we could get that antidepressant activity as a feature for the drug into the prescribing information locally, that would be a really nice boost to the value of the molecule."

He says the current interest in psychedelics highlights the need for new depression treatments beyond the current selective serotonin reuptake inhibitors (SSRIs, such as Prozac).

Gourlay dubs the chances of a complete Alzheimer's flop as unlikely, "as we have so much data showing the activity of the drug in the brain".

The company posted a full-year net loss of \$15.3m, having incurred \$19m of R&D costs. With \$16m in the bank, the company is well funded into 2027.

"If we found ourselves in a sticky situation, we have the time and the money and the right people to sort that out."

Actinogen shares have blipped 48% year on year, but more recently shareholders have kept a lid on their excitement.

"Every CEO says we are hopelessly undervalued, but the net present value of a positive result is enormously higher than our current valuation," Gourlay says.

A.k.a: 'we're dirt cheap, fill ya wellies'.

And – no - we are not licensed financial advisers.

Originally published as [Biocurious: It's spring, when a young man's fancy lightly turns to ... clinical trial results](#)

SA Business Journal Newsletter

Hi George, get trusted business news delivered direct to your inbox.

[Sign up](#)

Advertisement



7 Retirement Investment Strategies for Australians.

Fisher Investments

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription packages	About us	Help and support		Buy Search Sell Classifieds	 
Group/Corporate subscriptions	Meet the team	FAQs	Herald Sun	Find Your Local	
The Advertiser app	Job opportunities	Standards of practice	Courier Mail	Foxsports	
Today's Paper	Code of conduct	Letter to the Editor	The Daily Telegraph	Foxtel	
Newsletters	Subscription FAQs	Licensing & Reprints	news.com.au	Hipages	
	Subscription terms	Advertise with us	The Australian	Kayo	
	Financial Hardship Policy		The Mercury	My Tributes	
			Geelong Advertiser	Punters	
			The Cairns Post	odds.com.au	
			Gold Coast Bulletin	racenet.com.au	
			Townsville Bulletin	realestate.com.au	
			The Chronicle	News24 Australia	
			NT News	Coupons	
			The Weekly Times		
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times ACST (GMT +09:30). Powered by WordPress.com VIP

[Privacy policy](#) [Relevant ads opt-out](#) [Cookie policy](#) [Terms of use](#)